News
CRIS
3.980
+1.27%
0.050
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 14h ago
Curis reports Q3 EPS ($1.70), consensus ( $1.88)
TipRanks · 15h ago
Curis sees cash and cash equivalents sufficient into mid-2025
TipRanks · 15h ago
Curis Inc Q3 Loss Decreases, Beats Estimates
NASDAQ · 15h ago
Curis Q3 2024 GAAP EPS $(1.70) Beats $(1.83) Estimate, Cash And Cash Equivalents Of $31.6M Is Expected To Provide Cash Runway Into Mid-2025
Benzinga · 15h ago
*Curis 3Q Rev $2.93M >CRIS
Dow Jones · 15h ago
Curis GAAP EPS of -$1.70 beats by $0.17, revenue of $2.93M beats by $0.56M
Seeking Alpha · 15h ago
CURIS PROVIDES THIRD QUARTER 2024 BUSINESS UPDATE
Reuters · 15h ago
CURIS INC <CRIS.O> Q3 SHR VIEW $-1.83 -- LSEG IBES DATA
Reuters · 15h ago
*Curis 3Q Loss $10.1M >CRIS
Dow Jones · 15h ago
*Curis 3Q Loss/Shr $1.70 >CRIS
Dow Jones · 15h ago
Press Release: Curis Provides Third Quarter 2024 Business Update
Dow Jones · 15h ago
Earnings Scheduled For November 14, 2024
Benzinga · 20h ago
Curis: Q3 Earnings Snapshot
Barchart · 21h ago
Here's the major earnings before the open tomorrow
Seeking Alpha · 1d ago
Examining the Future: Curis's Earnings Outlook
Benzinga · 1d ago
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 1d ago
Weekly Report: what happened at CRIS last week (1104-1108)?
Weekly Report · 3d ago
Curis up 4% on emavusertib data in myelodysplastic syndrome
Seeking Alpha · 11/05 18:17
Weekly Report: what happened at CRIS last week (1028-1101)?
Weekly Report · 11/04 12:18
More
Webull provides a variety of real-time CRIS stock news. You can receive the latest news about Curis through multiple platforms. This information may help you make smarter investment decisions.
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.